Filter by: patients
What is Natalizumab?

Natalizumab is a monoclonal antibody given by infusion and used in the treatment of MS and Crohn's disease. It has been shown to slow progression and reduce relapses in MS. It is currently sold under the brand name Tysabri.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
MS (Multiple Sclerosis) 1399 497 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_none Efficacy_cant_tell
Other 34 9 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_none Efficacy_cant_tell
Improve mobility 26 12 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_none Efficacy_cant_tell
General health 23 6 Efficacy_major Efficacy_moderate Efficacy_none Efficacy_cant_tell
Fatigue 22 11 Efficacy_moderate Efficacy_slight Efficacy_none Efficacy_cant_tell
Stiffness/Spasticity 20 8 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_none

See all 1357 patients currently taking Natalizumab

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
37
Moderate
60
Mild
155
None
280

Commonly reported side effects, conditions, and hospitalizations associated with Natalizumab

Headaches 60
Tiredness 53
Fear of PML 25
Fatigue 17
Stomach pain 14
Urinary Tract Infection UTI 14
See all 183 reported side effects See top 6 reported side effects

Reported Dosages

Frequently reported dosages based on patients currently taking Natalizumab. See all 28 dosages

  monthly 300mg/15mL as needed 1 monthly 1 other monthly 30 mg monthly 200 mg monthly 300 mg monthly 300 mg/15 mL monthly 300 mg/15 mL every 4 weeks 300 mg/15 mL daily
  137 Number of Patients: 137 7 Number of Patients: 7 4 Number of Patients: 4 3 Number of Patients: 3 3 Number of Patients: 3 4 Number of Patients: 4 40 Number of Patients: 40 489 Number of Patients: 489 634 Number of Patients: 634 13 Number of Patients: 13  

Reported Stop Reasons

Why Patients Stopped Taking Natalizumab (multiple reasons could be selected)
Reason # Patients Percentage of patients
Doctor's advice 129   Doctor's advice: 34%
Side effects too severe 125   Side effects too severe: 33%
Other 117   Other: 31%
Did not seem to work 93   Did not seem to work: 25%
Personal research 31   Personal research: 8%
Expense 21   Expense: 6%
Course of treatment ended 11   Course of treatment ended: 3%
Change in health plan coverage 9   Change in health plan coverage: 2%
Not indicated 4   Not indicated: 1%

See all 371 patients who’ve stopped taking Natalizumab

Currently Taking Natalizumab

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more

Stopped Taking Natalizumab

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more

Reported Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Adherence of Natalizumab

Always
493 93%
Usually
25 5%
Sometimes
2 0%
Never
12 2%

Burden

Difficulty being on treatment

Burden of Natalizumab

Very
27 5%
Somewhat
70 13%
A little
141 27%
Not at all
294 55%

Cost

Paid out of pocket

Cost of Natalizumab

$200+
89 24%
$100-199
25 7%
$50-99
33 9%
$25-49
34 9%
< $25
183 49%

See more information, including instructions, precautions, side effects, and interactions.

Report created on February 12, 2012.